ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy

ConferenceNegative

AI Analysis

Summary

At the ESC 2026 conference, Cytokinetics and Arrowhead presented cardiovascular drug data to differentiate from competitors, while Alnylam faced pressure from a failed study.

Clinical Trial Data

Primary Endpoint

Not Met

Importance:4/10

Sentiment:

-0.30

ESC 2026cardiovascularclinical datatrial failurecompetitive positioning

Related Companies

$ALNY

Read the original article

Published by BioPharma Dive on August 31, 2026 2:49 PM

Read Original